GCC Psoriasis Treatment Market Outlook

with an estimated 3.2 million people suffering from psoriasis in the gcc region, it is no surprise that the demand for psoriasis treatment has seen an increase over the years. it is expected that both the prevalence rate of psoriasis as well as the public’s demand for treatment will continue to rise in the years to come. the treatment of psoriasis in the gcc countries depends largely on patient preference, cost and availability of medication. the most commonly prescribed treatment regimen combines both topical and systemic therapy. topical agents are usually employed first, followed by systemic agents when these fail to provide relief. biological treatment with monoclonal antibodies (or biologics), have also made an impact on the market due to their effects on the immune system. in terms of cost, topical agents are generally preferred since they are more economical and readily available. however, the high cost of systemic and biologic treatments is likely to drive the demand and sales of generic psoriasis medications in the gcc market. other treatments commonly prescribed includes phototherapy, nutraceutical therapies and traditional medicines. the significant potential of the psoriasis market in the gcc region has generated much interest from international pharmaceutical companies. some major players have already launched several blockbuster brands with a wide variety of psoriasis treatments, indicating to the strong presence of these products in the market. in summary, the demand of psoriasis treatment is expected to grow steadily over the next few years in the gcc region. this growth is likely to be driven by an increased number of patients suffering from psoriasis and the availability of new and innovative treatments. over the next decade, pharmaceutical companies should strive to develop safe and effective psoriasis treatments that are more affordable and accessible to those in need throughout the region.